Phase IB Study Using Sunitinib Plus Radiation Therapy for Cancer Patients

• Status: Completed
• Trial end date: 2010-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is using the combination of radiation and antiangiogenic agents (agents that destroy existing blood vessels) seems to be an approach to tumor cure.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University
• Collaborator: Pfizer
• Treatments: Sunitinib

Criteria

Inclusion Criteria:

• Minimum 2 week course of radiation therapy

• Solid tumors of the central nervous system, head and neck, thorax, and pelvis

Exclusion Criteria:

• Major surgery or radiation therapy within 4 weeks starting study treatment

• Grade 3 hemorrhage within 4 weeks